GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Cyclically Adjusted PS Ratio

Ocular Therapeutix (Ocular Therapeutix) Cyclically Adjusted PS Ratio : 16.95 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Ocular Therapeutix's current share price is $4.745. Ocular Therapeutix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.28. Ocular Therapeutix's Cyclically Adjusted PS Ratio for today is 16.95.

The historical rank and industry rank for Ocular Therapeutix's Cyclically Adjusted PS Ratio or its related term are showing as below:

OCUL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 7.8   Med: 17.52   Max: 38.39
Current: 16.87

During the past years, Ocular Therapeutix's highest Cyclically Adjusted PS Ratio was 38.39. The lowest was 7.80. And the median was 17.52.

OCUL's Cyclically Adjusted PS Ratio is ranked worse than
78.61% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs OCUL: 16.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ocular Therapeutix's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.164. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.28 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ocular Therapeutix Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ocular Therapeutix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Cyclically Adjusted PS Ratio Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 12.44 15.85

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.44 21.76 19.93 11.52 15.85

Competitive Comparison of Ocular Therapeutix's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Ocular Therapeutix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Cyclically Adjusted PS Ratio falls into.



Ocular Therapeutix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ocular Therapeutix's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.745/0.28
=16.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Ocular Therapeutix's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.164/129.4194*129.4194
=0.164

Current CPI (Dec. 2023) = 129.4194.

Ocular Therapeutix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.009 99.695 0.012
201406 0.032 100.560 0.041
201409 0.009 100.428 0.012
201412 0.024 99.070 0.031
201503 0.020 99.621 0.026
201506 0.021 100.684 0.027
201509 0.017 100.392 0.022
201512 0.018 99.792 0.023
201603 0.019 100.470 0.024
201606 0.018 101.688 0.023
201609 0.019 101.861 0.024
201612 0.021 101.863 0.027
201703 0.017 102.862 0.021
201706 0.015 103.349 0.019
201709 0.018 104.136 0.022
201712 0.017 104.011 0.021
201803 0.010 105.290 0.012
201806 0.017 106.317 0.021
201809 0.013 106.507 0.016
201812 0.012 105.998 0.015
201903 0.011 107.251 0.013
201906 0.015 108.070 0.018
201909 0.016 108.329 0.019
201912 0.046 108.420 0.055
202003 0.050 108.902 0.059
202006 0.027 108.767 0.032
202009 0.085 109.815 0.100
202012 0.104 109.897 0.122
202103 0.084 111.754 0.097
202106 0.143 114.631 0.161
202109 0.142 115.734 0.159
202112 0.149 117.630 0.164
202203 0.160 121.301 0.171
202206 0.149 125.017 0.154
202209 0.155 125.227 0.160
202212 0.170 125.222 0.176
202303 0.173 127.348 0.176
202306 0.195 128.729 0.196
202309 0.177 129.860 0.176
202312 0.164 129.419 0.164

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ocular Therapeutix  (NAS:OCUL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ocular Therapeutix Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730

Ocular Therapeutix (Ocular Therapeutix) Headlines